[Predictive and prognostic value of monitoring lymphocyte subsets in peripheral blood before and after chemotherapy in patients with metastatic breast cancer]

Beijing Da Xue Xue Bao Yi Xue Ban. 2016 Apr 18;48(2):304-9.
[Article in Chinese]

Abstract

Objective: To detect the proportion of lymphocyte subsets in peripheral blood of the advanced breast cancer patients before and after chemotherapy with docetaxel and thiotepa, as well as the association between the proportion of peripheral blood lymphocyte subsets with the response rate and prognosis.

Methods: The proportions of lymphocyte subsets (CD3+ T cell, CD3+/CD4+ T cell, CD3+/CD8+ T cell, CD3-/CD16+56+ NK cell, CD3+/CD16+56+ T cell, CD19+ B cell, CD4+/CD25+ T cell, CD8+/CD28- T cell, CD8+/CD28+ T cell) in the peripheral blood of 86 patients were analyzed with flowcytometry before and after chemotherapy. The result was analyzed in combination with clinicopathological data.

Results: The proportion of regulatory T cells (Treg) after chemotherapy in the disease control patients decreased significantly compared with that of the progressive patients (P=0.034). The difference of the proportions of Treg before and after chemotherapy affected significantly the overall survival (OS). The OS of the patients with decreased proportion of Treg was significantly longer than that of the patients with increased proportion of Treg, which was 23.5 and 9.4 months respectively (P<0.05).

Conclusion: The patients with decreased proportion of Treg after chemotherapy had higher response rate and better survival benefit.

MeSH terms

  • Breast Neoplasms / blood*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / immunology
  • Docetaxel
  • Female
  • Flow Cytometry
  • Humans
  • Lymphocyte Count
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / immunology
  • Prognosis
  • Survival Rate
  • T-Lymphocyte Subsets / cytology*
  • T-Lymphocytes, Regulatory / cytology*
  • Taxoids / therapeutic use

Substances

  • Taxoids
  • Docetaxel